Next Article in Journal
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy
Previous Article in Journal
Epitope Sequences in Dengue Virus NS1 Protein Identified by Monoclonal Antibodies
Article Menu

Export Article

Correction published on 24 August 2018, see Antibodies 2018, 7(3), 31.

Open AccessFeature PaperArticle
Antibodies 2017, 6(4), 15; https://doi.org/10.3390/antib6040015

Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings

1
MorphoSys AG, Discovery Alliance and Technologies, 82152 Planegg, Bavaria, Germany
2
Curie Institute, Inserm-Tumoral Angiogenesis Unit, Translational Research Department, Curie Hospital, 75005-Paris, France
*
Author to whom correspondence should be addressed.
Received: 15 September 2017 / Revised: 7 October 2017 / Accepted: 13 October 2017 / Published: 18 October 2017
Full-Text   |   PDF [11348 KB, uploaded 31 August 2018]   |  

Abstract

Background: The follicle-stimulating hormone (FSH)-receptor (FSHR) has been reported to be an attractive target for antibody therapy in human cancer. However, divergent immunohistochemical (IHC) findings have been reported for FSHR expression in tumor tissues, which could be due to the specificity of the antibodies used. Methods: Three frequently used antibodies (sc-7798, sc-13935, and FSHR323) were validated for their suitability in an immunohistochemical study for FSHR expression in different tissues. As quality control, two potential therapeutic anti-hFSHR Ylanthia® antibodies (Y010913, Y010916) were used. The specificity criteria for selection of antibodies were binding to native hFSHR of different sources, and no binding to non-related proteins. The ability of antibodies to stain the paraffin-embedded Flp-In Chinese hamster ovary (CHO)/FSHR cells was tested after application of different epitope retrieval methods. Results: From the five tested anti-hFSHR antibodies, only Y010913, Y010916, and FSHR323 showed specific binding to native, cell-presented hFSHR. Since Ylanthia® antibodies were selected to specifically recognize native FSHR, as required for a potential therapeutic antibody candidate, FSHR323 was the only antibody to detect the receptor in IHC/histochemical settings on transfected cells, and at markedly lower, physiological concentrations (ex., in Sertoli cells of human testes). The pattern of FSH323 staining noticed for ovarian, prostatic, and renal adenocarcinomas indicated that FSHR was expressed mainly in the peripheral tumor blood vessels. Conclusion: Of all published IHC antibodies tested, only antibody FSHR323 proved suitable for target validation of hFSHR in an IHC setting for cancer. Our studies could not confirm the previously reported FSHR overexpression in ovarian and prostate cancer cells. Instead, specific overexpression in peripheral tumor blood vessels could be confirmed after thorough validation of the antibodies used. View Full-Text
Keywords: antibody validation; cancer marker validation; FSH; FSHR; immunocytochemistry; immunohistochemistry; kidney cancer; ovarian cancer; prostate cancer antibody validation; cancer marker validation; FSH; FSHR; immunocytochemistry; immunohistochemistry; kidney cancer; ovarian cancer; prostate cancer
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

SciFeed

Share & Cite This Article

MDPI and ACS Style

Moeker, N.; Peters, S.; Rauchenberger, R.; Ghinea, N.; Kunz, C. Antibody Selection for Cancer Target Validation of FSH-Receptor in Immunohistochemical Settings. Antibodies 2017, 6, 15.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Antibodies EISSN 2073-4468 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top